{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T15:32:25Z","timestamp":1782228745684,"version":"3.54.5"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Finerenone is a novel third-generation, selective nonsteroidal mineralocorticoid receptor antagonist (MRA) that was approved by the Food and Drug Administration in July of 2021 for its use in adults with chronic kidney disease and Type II diabetes mellitus. Randomized controlled trials The Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease and Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease showed decreased adverse kidney and cardiovascular outcomes, respectively, in this population. The incidence of hyperkalemia, while higher in the study versus placebo group, was lower than older generations of MRAs (spironolactone and eplerenone) and proved to be an infrequent cause for drug discontinuation. The incidences of other adverse effects such as gynecomastia and acute kidney injury were similar in both the study and the placebo groups. This is the first third-generation MRA authorized to use to reduce the burden of cardiorenal disease.<\/jats:p>","DOI":"10.1097\/crd.0000000000000573","type":"journal-article","created":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T13:00:29Z","timestamp":1689080429000},"source":"Crossref","is-referenced-by-count":3,"title":["Finerenone: A Novel Third-Generation Mineralocorticoid Receptor Antagonist"],"prefix":"10.1097","author":[{"given":"Paola","family":"Gudino Flores","sequence":"first","affiliation":[{"name":"From the Division of Nephrology\/Department of Medicine, Jacobi Medical Center at Albert Einstein College of Medicine."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Diego","family":"Rodriguez Salazar","sequence":"additional","affiliation":[{"name":"From the Division of Nephrology\/Department of Medicine, Jacobi Medical Center at Albert Einstein College of Medicine."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan Lester","family":"Nahar","sequence":"additional","affiliation":[{"name":"From the Division of Nephrology\/Department of Medicine, Jacobi Medical Center at Albert Einstein College of Medicine."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belinda","family":"Jim","sequence":"additional","affiliation":[{"name":"From the Division of Nephrology\/Department of Medicine, Jacobi Medical Center at Albert Einstein College of Medicine."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,7,11]]},"reference":[{"key":"R1-20230711","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes.","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"R5-20230711","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1080\/17512433.2022.2094770","article-title":"Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes.","volume":"15","author":"Lerma","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R6-20230711","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1080\/13543784.2021.2002844","article-title":"Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics.","volume":"30","author":"Barrera-Chimal","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"R7-20230711","doi-asserted-by":"crossref","first-page":"T125","DOI":"10.1530\/JOE-16-0600","article-title":"30 years of the mineralocorticoid receptor: mineralocorticoid receptor antagonists: 60 years of research and development.","volume":"234","author":"Kolkhof","year":"2017","journal-title":"J Endocrinol"},{"key":"R8-20230711","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/clc.20324","article-title":"A comparison of the aldosterone-blocking agents eplerenone and spironolactone.","volume":"31","author":"Struthers","year":"2008","journal-title":"Clin Cardiol"},{"key":"R9-20230711","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000503712","article-title":"Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial.","volume":"50","author":"Ruilope","year":"2019","journal-title":"Am J Nephrol"},{"key":"R10-20230711","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/sj.ki.5000058","article-title":"The progression of chronic kidney disease: a 10-year population-based study of the effects of gender and age.","volume":"69","author":"Eriksen","year":"2006","journal-title":"Kidney Int"},{"key":"R11-20230711","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2012070718","article-title":"Kidney disease and increased mortality risk in type 2 diabetes.","volume":"24","author":"Afkarian","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"R12-20230711","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1053\/j.ackd.2014.03.003","article-title":"Cardiovascular complications of diabetic kidney disease.","volume":"21","author":"Palsson","year":"2014","journal-title":"Adv Chronic Kidney Dis"},{"key":"R13-20230711","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1124\/pr.59.3.3","article-title":"The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease.","volume":"59","author":"Kobori","year":"2007","journal-title":"Pharmacol Rev"},{"key":"R14-20230711","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1053\/j.ackd.2014.08.003","article-title":"Aldosterone blockade in CKD: emphasis on pharmacology.","volume":"22","author":"Schwenk","year":"2015","journal-title":"Adv Chronic Kidney Dis"},{"key":"R15-20230711","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/HYPERTENSIONAHA.114.04488","article-title":"Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases.","volume":"65","author":"Bauersachs","year":"2015","journal-title":"Hypertension"},{"key":"R16-20230711","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41440-018-0158-6","article-title":"Pathophysiological mechanisms of mineralocorticoid receptor-dependent cardiovascular and chronic kidney disease.","volume":"42","author":"Nishiyama","year":"2019","journal-title":"Hypertens Res"},{"key":"R17-20230711","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"R18-20230711","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"R19-20230711","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms.","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"R20-20230711","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ahj.2017.03.011","article-title":"True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: a meta-analysis.","volume":"188","author":"Vukadinovic","year":"2017","journal-title":"Am Heart J"},{"key":"R21-20230711","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury.","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"key":"R22-20230711","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial.","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"R23-20230711","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial.","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"R24-20230711","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes.","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"R25-20230711","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"R26-20230711","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1681\/ASN.2008121270","article-title":"Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes.","volume":"20","author":"Ninomiya","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R27-20230711","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1093\/eurheartj\/ehr017","article-title":"Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials.","volume":"32","author":"Holtkamp","year":"2011","journal-title":"Eur Heart J"},{"key":"R28-20230711","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1053\/j.ackd.2014.03.005","article-title":"Blood pressure, hypertension, RAAS blockade, and drug therapy in diabetic kidney disease.","volume":"21","author":"Yamout","year":"2014","journal-title":"Adv Chronic Kidney Dis"},{"key":"R29-20230711","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.mce.2011.05.005","article-title":"Central regulation of blood pressure by the mineralocorticoid receptor.","volume":"350","author":"Gomez-Sanchez","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"R30-20230711","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1161\/HYPERTENSIONAHA.122.19744","article-title":"Blood pressure and cardiorenal outcomes with finerenone in chronic kidney disease in type 2 diabetes.","volume":"79","author":"Ruilope","year":"2022","journal-title":"Hypertension"},{"key":"R31-20230711","doi-asserted-by":"crossref","first-page":"118","DOI":"10.15420\/aer.2018.18.2","article-title":"Risk factor management in atrial fibrillation.","volume":"7","author":"Brandes","year":"2018","journal-title":"Arrhythm Electrophysiol Rev"},{"key":"R32-20230711","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40256-019-00353-5","article-title":"Effect of spironolactone on atrial fibrillation in patients with heart failure with preserved ejection fraction: post-hoc analysis of the randomized, placebo-controlled TOPCAT trial.","volume":"20","author":"Neefs","year":"2020","journal-title":"Am J Cardiovasc Drugs"},{"key":"R33-20230711","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jacc.2011.11.063","article-title":"Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study.","volume":"59","author":"Swedberg","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R34-20230711","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jacc.2021.04.079","article-title":"Finerenone reduces new-onset atrial fibrillation in patients with chronic kidney disease and type 2 diabetes.","volume":"78","author":"Filippatos","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"R35-20230711","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jacc.2021.04.080","article-title":"Do mineralocorticoid receptor antagonists suppress atrial fibrillation\/flutter?","volume":"78","author":"Naccarelli","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"R37-20230711","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1097\/HJH.0000000000001671","article-title":"Effect of mineralocorticoid antagonists on blood pressure lowering: overview and meta-analysis of randomized controlled trials in hypertension.","volume":"36","author":"Bazoukis","year":"2018","journal-title":"J Hypertens"},{"issue":"Suppl 1","key":"R38-20230711","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00004836-198100031-00016","article-title":"Diuresis in the ascitic patient: a randomized controlled trial of three regimens.","volume":"3","author":"Fogel","year":"1981","journal-title":"J Clin Gastroenterol"},{"key":"R39-20230711","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1517\/14656566.9.4.509","article-title":"Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.","volume":"9","author":"Karagiannis","year":"2008","journal-title":"Expert Opin Pharmacother"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000573","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T13:00:53Z","timestamp":1689080453000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,11]]},"references-count":35,"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000573","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,11]]}}}